OOIR: Observatory of International Research

Papers

(The TQCC of Alzheimers & Dementia is 1. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-12-01 to 2025-12-01.)

Article	Citations
High‐fat diet reduced dendritic spine density, but it did not affect cognitive function in spontaneous diabetic torii rats	2446
RBFOX1 is regulated by the adenosine 2a receptor and is ubiquitinated in tau tangles in Alzheimer’s disease	1796
Locus coeruleus hyperactivity in middle age may be associated with better cognitive performance	1354
Trajectories of Neurological Recovery 12 Months after Hospitalization for COVID‐19: A Prospective Longitudinal Study	1309
Alzheimer's disease‐induced phagocytic microglia express a specific profile of coding and non‐coding RNAs	625
CSF biomarker concordance with amyloid PET in Phase 3 studies of aducanumab	431
Diversity, Equity and Inclusivity‐ Low and Middle Income countries and the Lancet commission	355
CT1812 biomarker signature from a meta‐analysis of CSF proteomic findings from two Phase 2 clinical trials in Alzheimer's disease	345
Intracranial arteriosclerosis and the risk of dementia: A population‐based cohort study	282
Prevalence of neuropsychiatric conditions and cognitive impairment in two parallel, aging study cohorts from rural and urban India	210
Cis p‐tau underlies vascular contribution to cognitive impairment and dementia, but is effectively targeted by immunotherapy	201
The Design of SPRINT MIND and SPRINT MIND 2020	181
The Global Neurodegeneration Proteomics Consortium ‐ Biomarker and Drug Target Discovery Across >40,000 Biosamples for AD, PD, ALS, FTD, and Aging	181
Rapid discovery and optimization of novel brain shuttles and shuttle‐enabled anti‐amyloid therapeutics using multiplexed in vivo biologics design	172
Survey on knowledge of Uruguayan neurologist about the FINGER intervention	166
Approach for developing interpretative cut‐points during implementation of a plasma p‐tau217 assay in the clinical laboratory	164
Use of a blood‐based amyloid test for screening in INVOKE‐2: a phase 2 randomized, double‐blind, placebo‐controlled study evaluating AL002 in early Alzheimer’s disease	151
Exploring Alzheimer’s disease progression through the lens of genetics and sleep disturbances	148
The power of cognitive rehabilitation in Alzheimer’s disease ‐A Systematic review and meta analysis	143
Examining the impact of hormone therapy and Alzheimer’s disease risk factors on depressive symptoms in the Harvard Aging Brain Study	137
Relationship between perivascular spaces and white matter hyperintensities in Alzheimer’s disease	131
Social Engagement as a Protective Factor for Cognition in Older Adults: Examining Sex and Race Differences	123
Influence of tau on non‐traditional memory scores in early‐onset Alzheimer’s disease	118
The Types and Consistency of Participant‐Specified Proxies During SPRINT	118
Neural flexibility as a promising biomarker for Alzheimer’s Disease	118

Longitudinal multicenter head‐to‐head harmonization of tau‐PET tracers: an overview of the HEAD study cohort	112
Clinical validation of the Eli Lilly SPX P‐tau217 blood‐based immunoassay as a laboratory‐developed test (LDT)	112
MRI‐guided Clustering of Alzheimer’s Disease patients: A post‐hoc analysis of Phase 3 Trial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease	103
Subjective cognitive decline across ethnoracial groups in the A4 study	101
Identifying individuals with non‐AD co‐pathologies: A precision medicine approach to clinical trials in sporadic AD	97
Dissipating the fog: Cognitive trajectories and risk factors 1 year after COVID‐19 hospitalization	91
Rationale for an anti‐inflammatory insulin sensitizer in a phase 3 Alzheimer's disease trial	89
Donepezil treatment is associated with improved outcomes in critically ill dementia patients via a reduction in delirium	88
Evaluation of Two Plasma pTau217 Simoa Assays Against Amyloid‐PET	87
Lean mass, grip strength, and hospital‐associated disability among older adults in Health ABC	86
“Brain‐IT”: Exergame training with biofeedback breathing in neurocognitive disorders	83
Impact of learning amyloid PET results on test‐related distress and concern about dementia in a cognitively unimpaired observational cohort	83
Decorin is an early CSF biomarker of Alzheimer’s Aβ amyloidosis	83
An international core outcome set for primary progressive aphasia (COS‐PPA): Consensus‐based recommendations for communication interventions across research and clinical settings	83
The use of the Cognitive Change Questionnaire by community health workers as dementia screening method	81
The moderating effect of APOE E4 on the association of plasma biomarkers with markers of cognition and brain health in Alzheimer’s disease	81
Policy recommendations from the perspective of health professionals who work with people with dementia in public tertiary hospitals in China	80
The effect of prolonged lockdown due to COVID‐19 on demented patients of different stages and on their caregivers	78
The dementia policies in Australia relating to the COVID‐19 pandemic	75
The association between diabetes and Alzheimer’s disease pathophysiology	74
Association of air quality reduction with incident dementia: Effects of natural course and hypothetical air pollutant interventions using g‐computation	74
Outreach and recruitment of African Americans for Alzheimer’s disease studies during the COVID‐19 pandemic	74
Assessing sex differences between mid‐life cardiovascular conditions or risk factors and mid‐life cognition decline	74
Fish intake and MRI burden of cerebrovascular disease in older adults	72
The impact of the COVID‐19 pandemic on cognitive health	72
Association of anticholinergic medication and AD biomarkers among cognitively normal late middle‐age adults: Results from the Wisconsin Registry for Alzheimer's Prevention (WRAP)	72
Iron intake, brain iron, and Alzheimer’s disease among community‐dwelling older adults	72
Comparative efficacy of cholinesterase inhibitors and memantine on cognition in AD patients with application of network meta‐analysis	71
The troubles and needs of family caregivers of older adults with moderate to severe dementia	71
Study Design of FINGER‐NL: a Multidomain Lifestyle Intervention in Dutch Older Adults to Maintain Optimal Cognitive Functioning	71
Association of neighborhood socioeconomic disadvantage and cognitive decline	71
Unsupervised Learning‐based Drug Repositioning for Alzheimer’s Disease Targeting Brain Cell Type Specific Genetic Subtypes	71
Issue Information	71
Impact of Mid‐ and Late‐Life Diabetes in the Trajectories of Cognitive Aging in a Bi‐ethnic Cohort of Mexican Americans and Non‐Hispanic White Older Adults	70
Development of pyroptosis inhibitors for Alzheimer’s disease	69
Prevalence of Alzheimer’s disease (AD) dementia and mild cognitive impairment (MCI) in the United States Medicare population	67
Analytical Choices of Timescale in the Presence of Practice and Cohort Effects in Longitudinal Cognitive Aging Research: A Simulation Study Using Linear Mixed‐Effects Models	66
Cognitive impairment prevention and healthy aging. A multidisciplinary team work	66
The heterogeneity of subjective cognitive decline: A data‐driven approach on a population‐based sample	65
Comparison of Vascular Health in Super‐Agers and Cognitively Normal Adults 80 Years and Older	65
Biomarker driven enrichment strategies for tau pathology in AD clinical trials	62
Dementia‐inclusive radio series ‘Talkin’ About Neurodegeneration'—A look under the dementia umbrella and a follow‐on series to award‐winning ‘Voyage Around My Brain’ on NearFM	62
Combination of baicalein and trans‐chalcone synergistically reduces amyloid beta and its toxicity in yeast	61
Analysis of the ACE‐R’s sub‐items that best differentiate healthy controls, amnestic MCI and non‐amnestic MCI	61
Improved functional connectivity after a 6‐month ketogenic supplementation in mild cognitive impairment	61
Tau368 in cerebrospinal fluid is associated with severity of tau pathology load in the Alzheimer’s continuum	60
Concordance and diagnostic accuracy between Innotest and two fully automated platforms: Elecsys and Lumipulse	59
LANGaware: Introducing the right solution for the early detection of neurodegenerative and psychiatric diseases	59
Integrated analysis of in vivo retinal perivascular amyloid imaging and cognition	59
Short‐term Sirolimus Treatment Restores Hippocampus and Caudate Volumes and Global Cerebral Blood Flow in Asymptomatic APOE4 Carriers Compared with Non‐carriers	57

Circulating extracellular vesicles of neurovascular origin are elevated in women with severe preeclampsia years after their affected pregnancies	57
Correction to “Using remote, digital, multi‐day testing to characterize long‐term forgetting in cognitively unimpaired older adults”	57
Using an entorhinal cortex‐based virtual reality navigation task to differentiate between individuals with and without subjective cognitive decline	56
Regional correlation analysis between neuronal metabolism and synaptic density using [18F]FDG and [11C]UCB‐J	56
Relationship between amyloid and tau levels and its impact on tau spreading	55
Speed of cognitive decline in biomarker stratified SCD subgroups	55
A simple, automated, speech‐based and AI‐enhanced screener for mild cognitive impairment and amyloid beta positivity	55
Automating the verbal paired associates test to assess memory remotely and at scale	55
Cognitive correlations with amyloid, tau and neurodegeneration PET across the Alzheimer’s disease age spectrum	54
Memory decline is not normal, healthy brain aging	54
Comparison of remote and in‐person digital speech‐based measures of cognition	53
Functional connectivity measurements in APP/PS‐1 mice revealed hypo‐connectivity with transient hyper‐connectivity	53
The chauffeur who banged cars happily: an interesting case of rapidly progressive strategic infarct dementia	53
Meaning from tragedy: exploring attitudes toward dementia patient participation in research	53
Feasibility of the occupational therapy protocol TAP (Tailored Activity Program) for the management of behaviors in a dementia hospital unit: Preliminary results from a pilot study	53
Autophagy and lysosomal defects in cells expressing disease‐associated tau	52
Issue Information	52
Trajectories of self‐rated concerns in individuals developing cognitive decline	52
	52
Visual memory test equal to commonly used verbal memory test in predicting tau in the medial temporal lobe	52
A Study of Factors Influencing Quality of Life among Community Dwelling Elderly in Korean Urban Community	51
Association of life‐course traumatic brain injury with the risk of dementia: a nationwide twin study	51
Comparing associations of Alzheimer’s disease plasma biomarkers with remote self‐administered cognitive measures versus in‐person neuropsychological tests	50
A 10‐minute Digitally Administered and Scored Neuropsychological Protocol Assessing Executive Control and Episodic Memory	50
Identification of objective cognitive decline in preclinical Alzheimer’ disease	50
A Rule‐Based Framework to Identify Severity of Dementia from Unstructured Electronic Health Record Data	50
Decline in everyday functioning in relation to cerebral tau burden across the clinical spectrum of Alzheimer’s disease	50
Hearing impairment is associated with cognitive decline, brain atrophy and tau pathology	49
Prevalence of risk factors for dementia and association with cognitive alterations in an elderly population from the South of Brazil	49
Preventing cognitive decline using portable, non‐invasive sleep enhancement.	49
	49
Sex modifies the associations of regional fat with cognitive functioning and AD‐related brain volumes, in Israeli middle‐aged adults at high AD risk	48
Inflammation and working memory performance in everyday life: Gender differences among older adults with and without cognitive impairment	48
Characterising the covariance pattern between lifestyle factors and structural brain measures: a multivariable study of two cohorts of older adults	47
A Comparison of the Prevalence of Diabetes between Aging Rural and Urban Indians.	47
Transition in the cognitive continuum from normal cognition to dementia: the interplay of lifelong cognitive reserve with brain aging and genetic predisposition	47
Recruitment data of the HAPPCAP‐AD (Human‐APPlication Combined Approach for Prevention of Alzheimer’s Disease): a feasibility study	47
Reducing Risk of ADRDs: Innovative Framework to Inform Behavior Change	47
COVID‐19 Infection and Dementia: Analyses of time‐varying risk, subtypes, and subpopulations from the UK Biobank	47
Social media responses to the approval of lecanemab in Japan: sentiment analysis	46
Impact of Metabolic Syndrome Longitudinal Changes on Cognitive Health: A 10‐Year Follow‐up Study in Middle‐Aged Adults	46
Cognitive symptoms and medical history prior to mild cognitive impairment and dementia diagnosis: a retrospective case‐control study using Dutch primary care data	46
Baseline Frailty and Domain‐specific Cognitive Declines in Healthy and MCI Older Adults	46
Engaging and Recruiting Latino‐led Community Organizations to Build Workforce Capacity in AD/Brain Health Prevention Research	46
Relation Between Educational Attainment and Cerebral Small Vessel Disease: the Framingham Heart Study	46
Social Engagement is associated with better cognition in Quilombola Communities: Insights for Engaging underserved Brazilian Populations in Alzheimer’s Disease Research	46
Are there trends towards compression of morbidity for dementia? Evidences from four international population‐based cohorts	45
Impact of Site Size on Data Quality in Early Alzheimer’s Disease Clinical Trials	45
CD33 competitive inhibitor peptide IMAD‐001 modulates innate immunity in Alzheimer’s disease	45
Improvement of Knowledge and Research Attitudes on Preclinical Alzheimer’s Disease Trials through Community‐based Education Among Underrepresented Korean, Filipino, and Hispanic Americans	45
Delivery of incretin receptor agonists to the brain	45
Additive Impact of Cardiometabolic Multimorbidity and Depression on Cognitive Decline: Findings from Multi‐Regional Cohorts and Generalization from Community to Clinic	45
Preliminary Evidence for the Combined Efficacy of Focused Ultrasound Blood‐Brain Barrier Opening and Delivery of a Novel Anti‐Amyloid Re Complex for Memory Improvement in a 3xTg‐Alzheimer’s Disease Mo	44
Incorporating clinical trial outcomes in health economic evaluations of disease‐modifying therapies for AD	44
Clinical outcome assessments for LBD trials – Should we borrow?	43
The association between air pollution and dementia: results from the Cognitive Function and Ageing Study II and Wales	43
Microglial‐targeted nSMase2 inhibitor fails to reduce tau spread in the animal model of Alzheimer’s disease	43
Neuroinflammation is associated with the rising of early Alzheimer’s disease pathology in amyloid‐negative elderly	42
In Vivo Head‐To‐Head Comparison of [¹⁸F]GTP1 and [¹⁸F]PI2620 in Alzheimer’s Disease	42
Exploring Inflammasome/Cytokine/Insulin cascade as converging landscape for AD, Schizophrenia(SCHIZO), and COVID‐19 syndrome: synthesis of evidence and Post‐hoc analysis of Ginsans‐115 RCT in treatmen	42
Discerning neurodegenerative and aging genetic influences on hippocampal subfields trajectories in the Alzheimer’s disease continuum	42
Dynamic Light Scattering Spectroscopy as an Early Biomarker of Alzheimer’s Disease	42
Addressing the gaps of the functional neuroimaging in young APOEe4 carriers: A systematic review and Graph Theoretical analysis of brain connectivity	42
Depression in Alzheimer’s disease hospitalized patients: A descriptive analysis of a nationwide database	41
From identification to implementation: state of the art in biomarkers for immune function in CSF and blood	41
Cerebral Small Vessel Disease and Gait Speed in Older Adults without Dementia	41
Exploring the basis of phenotypic diversity in Alzheimer’s disease	41
Automated word class and person usage metrics as markers of Alzheimer’s and frontotemporal dementia	41
Clinical profile of primary progressive Aphasia in Peru: Case series from a Neurological care center	41
Cognitive health risks posed by social isolation and loneliness in older Korean Americans	41
Development of an artificial intelligence approach that employs genomic and brain imaging features to improve the diagnosis of Alzheimer’s Disease (AD)	41
Hub vulnerability and short path length to entorhinal cortex are associated with tau binding in Alzheimer’s disease: a combined MEG/PET study	40
Is QEEG an effective biomarker in predicting cognitive decline?	40
Who is at risk of dementia? Trajectories of cognitive decline from mild cognitive impairment to dementia and the factors which mediate this decline	40
Prevalence and pathological correlates of unawareness of memory impairment in non‐demented individuals with autosomal dominant Alzheimer’s disease: an item‐level investigation of the Memory Complaints	40
Language, cognitive and neuroimaging determinants of Primary Progressive Aphasia in Hebrew Speakers, a case series	39
Cognitive aging outcomes are related to both tau pathology and maintenance of cingulate cortex structure	39
Cerebellar‐cortical functional connectivity is associated with Alzheimer’s disease pathology and cerebellar atrophy	39
Investigation of sex differences in mutation carriers of the Dominantly Inherited Alzheimer Network	39
PENSA study for the prevention of cognitive decline in APOE‐ɛ4 carriers with subjective cognitive decline: Description of baseline demographic and neuropsychological data of the study population	39

The Advanced Therapeutics for Alzheimer’s Disease Review Board: A Multidisciplinary Model to Facilitate Safe Access to Lecenemab across the Sutter Health System	39
Neuroinflammatory biomarkers in neurodegenerative disease: Insights from the ONDRI Cohort	39
Hyperintensity on Diffusion‐Weighted MRI and Clinical Correlations in Probable Creutzfeldt‐Jakob Disease	38
A cross‐sectional analysis of Alzheimer’s disease plasma biomarkers and gait variables in cognitively normal older adults	38
EEG microstates as a “real time” feedback for rTMS treatment efficacy in MCI subjects	38
Plasma biomarker and neuroimaging changes in a Chinese community aging cohort: The Greater‐Bay‐Area Healthy Aging Brain Study (GHABS)	38
Amyloid‐Beta PET Synthesis from Structural MRI: A Potential Alternative Method for Alzheimer’s Disease Screening	38
The influence of amyloid on tau deposition in clinically obese participants	38
DETECT‐AD (Digital Evaluations and Technologies Enabling Clinical Translation for Alzheimer’s Disease): A simulated anti‐amyloid clinical trial using digital biomarkers as primary outcome measures	38
The Association between the Body Fat Localization, Insulin Resistance, and Amyloid Burden in Midlife	38
APOEε4 facilitates the accumulation and connectivity‐mediated spreading of tau pathology at lower amyloid levels	38
Gender Differences in Frontotemporal Dementia: Clinical, Brain Structural, White Matter Hyperintensity, and Brain Metabolic Features	38
Pupillometry as a marker of arousal and in relation to cognition and cortical dynamics in Alzheimer’s disease	38
Proteomics identification of novel proteins dysregulated in Alzheimer’s Disease with potential as blood‐based biomarkers and related to Amyloid‐Beta Plaques	37
Effect of administration of vitamin D3 alone or combined with donepezil on the memory of adult and aged ovariectomized rat	37
Complement receptor 1 length polymorphism impacts glial functions relevant to Alzheimer’s disease	37
Preserved transcriptional networks in immune signaling pathways associated with chronic disease identified in Alzheimer’s disease and Parkinson’s disease, cross‐tissue analysis	37
In vitro activity of polyphenol‐rich extract of sorghum relevant to treatment of Alzheimer’s disease	37
Dynamic disease‐associated gene regulatory transitions unmask genetic risk associated neurodegenerative cell states	37
Iron–induced, sex‐specific alterations of mitochondrial bioenergetic function and increased amyloid beta plaque size in 5xFAD mice	37
Myricetin prevents high molecular weight Aβ_1‐42 oligomer‐induced neurotoxicity through antioxidant effects in cell membranes and mitochondria	37
Digitizing the Trails Making Test for Automatic Detection of Cognitive Impairment: Validity and Reliability	36
Persistent DNA damage response drives cGAS‐STING mediated neuroinflammation in a mouse model of tauopathy	36
Interaction between polymorphisms in MBP and EIF2B5 genes is significantly associated with Alzheimer’s disease	36
Increased fibrin deposition in the brains of individuals with Down syndrome and Alzheimer’s disease	36
The role of impaired oxidative base lesion repair in Alzheimer’s disease	36
Relationships between Circulating Monocyte and Brain Transcriptional Profiles in Nonhuman Primates Consuming Mediterranean versus Western Like Diets	36
Production and characterization of human tau protein with site‐specific phosphorylation utilizing E. coli with an expanded genetic code	36
Expanded bile acid annotations linked to diet and AD biomarkers	36
Prevalence of dementia diagnoses in a safety net health system	35
Hypogyrification in midlife women with surgical menopause, a population at risk for late life Alzheimer’s	35
Multiple pathological mechanisms of Bin1 for tau aggregation and propagation	35
Retinal Examination in Neurodegenerative Diseases of the Brain	35
Integrative Analysis of Genetic Network and Brain Imaging using Generative Models for Alzheimer’s Disease Prediction	35
Bin1 regulates synaptic endocytic trafficking compromised by Alzheimer’s genetic risk variants	35
Anosognosia and caregiver distress independently identify subjects at high risk of developing dementia of Alzheimer’s type	35
	35
Whole blood DNA methylation profiles of Alzheimer’s disease differ across ancestrally diverse populations	35
Longitudinal neuropsychological evaluation allows diagnosis of MCI with less severe memory change	34
Association Between Neuropsychiatric Symptoms and Blood‐Based Autoantibody Biomarkers	34
Targeted Multiplexed MALDI MS Platform Enables Detection of Novel Pathogenic Forms of Tau, Amyloid Beta and Alpha Synuclein	34
Impaired retinal capillary function in patients with clinical Alzheimer’s disease	34
Characterization of behavioral changes, MRI brain volumetry and brain metabolic profile of 5xFAD mouse model of Alzheimer’s disease	34
Association between plasma inflammatory biomarkers and [¹⁸F]FDG‐PET signal in a transgenic amyloid rat model	34
Relationships between cerebral tau and glucose metabolism in cognitively normal older adults	34
Characterizing progressive speech changes in prodromal‐to‐mild Alzheimer’s disease using natural language processing	34
Characteristics of peripheral immune system in a novel App^NL‐G‐F knock‐in mouse model of Alzheimer’s disease	33
CaMKIIα signaling is required for the neuroprotective effects of Dl‐3‐n‐butylphthalide in Alzheimer’s disease	33
Re‐evaluation of the genetic role of a rare APOE variant (L28P; APOE^4Pittsburgh*) in late‐onset Alzheimer disease	33
Methods in Prioritizing Pathways and Targets from Expression Data	33
	33
Systemic and central nervous system metabolome changes associated with Ginkgo biloba treatment in non‐demented subjects	33
Transgender adults report greater cognitive and related functional challenges: Findings from the 2015‐2019 Behavioral Risk Factor Surveillance System	33
2021 Annual Report of Japanese Brain Bank Network for Neuroscience Research	33
Deep learning‐based estimation of future brain atrophy using baseline MRI and PET	32
Addressing the gaps of the functional neuroimaging in young APOEe4 carriers: A systematic review and Graph Theoretical analysis of brain connectivity	32
Myelin water imaging with clinically feasible scan time: the accelerated BMC‐mcDESPOT (aBMC‐mcDESPOT) method	32
Synapse loss in early‐ and late‐onset Alzheimer’s Disease assessed by 18F‐SynVest‐1	32
The Effect of COVID‐19 Lockdown on Dementia Caregivers in the U.S.	32
Family care partners experiences of delirium in caring for a person with dementia: Qualitative descriptive study	32
Ancestry‐Specific eQTL Associations in AA/NHW Alzheimer Disease Cohorts	32
AD‐Associated Variants Directly Impair Surface Interactions Between the Hydrophobic Site of TREM2 and the Hinge Region of ApoE	32
Loss of apolipoprotein E exacerbates microglial and astrocyte reactivity to sustained systemic glucocerebrosidase inhibition	32
Aberrant resting‐state functional connectivity of the default‐mode network relates to cognitive decline in the earliest Alzheimer’s continuum	32
Contrast of Early Phase Amyloid PET	32
Intracranial atherosclerosis is linked to lower volume in the posterior portion of the hippocampus	32
The Relationship of Neuropsychiatric Symptoms and ADRD Pathologies	32
Modifiable dementia risk factor associations with AT(N) biomarkers: Findings from the European Prevention of Alzheimer’s Dementia study	31
Lexicon of Dementia: A cross‐linguistic study of the impact of dementia terminology on cultural perceptions	31
Subjective Social Status, Brain Health, and Cognitive Reserve Across Race/Ethnicity and Sex/Gender	31
Examining the Effect of Work‐Life Imbalance on Cognitive Complaints	31
Prevalence of Dementia among Malawian adults with HIV and without HIV: A Medical Record Review	31
Socioeconomic and health‐related disparities associated with healthy brain aging in Latin American countries	31
Plasma and neuroimaging biomarkers of small vessel disease and Alzheimer’s disease in a diverse cohort	31
Exploring Social Engagement in a Virtual Participatory Culinary Nutrition Education Intervention for Dementia Prevention	31
Optimizing Mealtime (OPTIMAL): A Pilot Trial of a Person‐Centered Care Program in Nursing Home Care Staff and Residents with ADRD	31
Examination of intrapersonal and affective characteristics associated with everyday function among older adults with subjective cognitive decline	31
Fatigue predicts 10‐year risk of incident dementia in a population representative cohort of United States Medicare beneficiaries	30
Depressive Symptoms and Cognitive Function in Older Adults with Subjective Cognitive Decline: Longitudinal Findings From 2010 to 2020	30
Assessing Short‐term Memory with Different Memory Modalities in Mild Cognitive Impairment	30
Association between pulmonary function and cognition in urban Indian adults – A cross sectional analysis	30
Comparing the Brief Assessment of Cognitive Health and Montreal Cognitive Assessment: Test‐retest reliability and sensitivity to cognitive change in older adults	30
Cognitive Impairment in Firefighters and Emergency Medical Services Workers after Severe WTC Exposures	30
Effects of lifestyle factors on Alzheimer’s disease symptoms in adults with Down syndrome	30
Standardizing Care for Agitation in Alzheimer’ Dementia: Results from a Randomized Controlled Trial of an Integrated Care Pathway versus Usual Care ‐The StaN trial	30
Passively collected smartphone behaviour as a reliable and feasible measure for global cognition in Alzheimer’s Disease	30
Challenges to Dementia Care in El Salvador: Perspectives from Geriatricians of the Salvadoran Older Adults Study	30
Simian varicella virus infection in rhesus macaques is associated with amyloid deposition in multiple organs and arteries and production of an amyloidogenic state	30
Association of CSF AD biomakers and lifestyle factors with neuropsychiatric symptoms among non‐demented older persons	30
Cognitive Disparities in the Wayuu Indigenous Population: Insights from Neuropsychological Assessment	30
Anti‐ulcer drug teprenone clinical trial	29
A Placebo‐Controlled Phase I Study in Healthy Subjects Assessing NVG‐291, which Targets CNS Receptor Protein Tyrosine Phosphatase Sigma (PTPσ)	29
Neuropathology of a patient with AD treated with low doses of verubecestat	29
PDE5 inhibitors against synaptic and cognitive impairment in Alzheimer’s disease and related dementia	29
WVE‐005, a stereopure antisense oligonucleotide for MAPT silencing in tauopathies	29